The importance of heart rate control in the management of heart failure FLORIAN CUSTODIS, JAN CHRISTIAN REIL, ULRICH LAUFS, MICHAEL BÖHM
|
|
- Berniece Stanley
- 6 years ago
- Views:
Transcription
1 VIEWPOINTS VIEWPOINTS The importance of heart rate control in the management of heart failure FLORIAN CUSTODIS, JAN CHRISTIAN REIL, ULRICH LAUFS, MICHAEL BÖHM Heart rate is a major determinant of myocardial oxygen demand, coronary blood flow and myocardial performance and affects nearly all stages of cardiovascular disease. The recent literature indicates that an elevated resting heart rate represents a cardiovascular risk factor, independent of currently accepted risk factors and other potentially confounding demographic and physiological characteristics. Elevated heart rate is one of the key findings in acute and chronic heart failure and has been shown to be an important predictor of morbidity and mortality. Ivabradine, an inhibitor of the I(f) channel in the sinoatrial node, reduces heart rate without any effect on cardiac contractility and without lowering blood pressure. The effects of additive heart rate reduction on outcomes in patients with heart failure were tested in the BEAUTIFUL and the SHIFT trial. Results of the BEAUTIFUL trial show that patients with ischemic heart disease and a heart rate above 70 bpm exhibit an adverse prognosis concerning coronary events, however the trial showed no effect with regard to the primary endpoint. However heart rate reduction with ivabradine added to the standard pharmacologic treatment improved the prognosis in the subgroup of CAD patients with reduced left ventricular function and a resting heart rate of more than 70 bpm. Results of the SHIFT trial support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm the role of heart rate as a risk factor for patients with severe left ventricular dysfunction. Keywords: Heart rate. Cardiovascular risk factor. Ivabradine. Heart failure. Heart rate - an easily accessible clinical variable - underlies the control of the autonomic nervous system. During physical activity heart rate accelerates due to an increase of the sympathetic and a decrease of the parasympathetic tone. Besides myocardial wall tension and contractility heart rate determines myocardial energy requirements and oxygen demand and defines cardiac output 1. In the past decades an extensive set of investigations focussed on the predictive value of heart rate for the general population and individuals affected by cardiovascular disease. The recent literature indicates that an elevated resting heart rate represents a cardiovascular risk factor, independent of currently accepted risk factors and other potentially confounding demographic and physiological characteristics 2-5. Elevated resting heart rate has been shown to be an important predictor of Klinik für Innere Medizin III. Kardiologie, Angiologie und internistische Intensivmedizin. Dirección postal: Florian Custodis. Universität des Saarlandes Homburg/Saar. Germany. florian.custodis@uks.eu The authors declare no conflict of interest in this article. Received: 30-SEP-2010 Accepted: 08-OCT-2010 mortality in cardiovascular disorders such as coronary artery disease, myocardial infarction, and chronic heart failure 6-8. Experimental and clinical evidence suggest that sustained elevations in heart rate irrespective of the underlying trigger play a direct role in the pathogenesis of atherosclerosis and myocardial injuries, affect initiation and progression as well as the severity of the disease and contribute to precipitation of vascular and myocardial events 9-13 (Table 1). PATHOPHYSIOLOGY Under pathophysiological circumstances heart rate becomes relevant in coronary artery disease affecting both sides of myocardial oxygen balance. An increased heart rate contributes to an imbalance by both decreasing supply and increasing demand thereby TABLE 1 CONSENSUS RECOMMENDATIONS FOR MEASUREMENT OF RESTING HEART RATE* -patient should rest for at least 5 min. -pulse palpation over a 30 sec. period. -palpation in sitting posture. -at least two measurements. *: adapted from Rev Fed Arg Cardiol 2010; 39 (4):
2 FLORIAN CUSTODIS ET AL leading to myocardial ischemia and subsequent angina 1. With intact coronary circulation, metabolic vasodilation serves to increase coronary blood flow to match an increased oxygen demand. However in the presence of a severe coronary stenosis, when the autoregulatory capacity of the coronary circulation fails to maintain a normal coronary blood flow any further increase in heart rate (or more precisely, any further reduction in diastolic perfusion time) will compromise coronary blood flow 14. In the case of regional myocardial ischemia, where a severely stenotic coronary artery is connected via collaterals with an intact coronary artery a typical redistribution (steal) of blood towards the intact coronary artery develops. In addition to such steal phenomenon, the hemodynamic severity of a coronary stenosis is increased at higher heart rate due to increased turbulence. This effect serves to further compromise coronary inflow 15. Elevated heart rate at rest is one of the key findings in acute and chronic heart failure and represents a negative prognostic predictor 16. Neuroendocrine mechanisms, such as increases of sympathetic activity and activity of the renin-angiotensin-aldosterone system, are activated in heart failure and contribute to a progression of ventricular dysfunction 17. Increased sympathetic activity is associated with a rise of circulating catecholamines - especially norepinephrine - leading to a positive chronotropic stimulation and resulting in accelerated resting heart rate. Such an increase in heart rate may directly affect myocardial performance by alteration of oxygen consumption, reduction of diastolic filling and coronary perfusion by impairment of relaxation and finally proarrhythmic effects. Furthermore, high heart rates per se can cause heart failure. As known from patients with atrial fibrillation and an inadequate heart rate control, a decline in ventricular ejection fraction can occur within days 18. After control of ventricular rate, gradual improvement of left ventricular function can be achieved in the following weeks and months. Under physiologic conditions the heart exhibits a positive force-frequency relationship (Bowditch-effect) and develops a stepwise rise in contractility when heart rate is accelerated. This positive force-frequency relationship is abolished or even inverted in the failing myocardium. The heart rate-associated impairment of relaxation is especially important in hearts with diastolic heart failure 19. Diastolic heart failure is characterised by an impaired relaxation and/or decreased compliance of the ventricle while systolic function is largely preserved. Elevated heart rate shortens diastolic duration thereby additionally constrains ventricular filling and compromises the preexisting relaxation disturbance of these hearts. HEART RATE IN THE MANAGEMENT OF HEART FAILURE THERAPEUTIC APPROACH Based on the evidence from a multitude of clinical studies and large heart failure trials it is common knowledge that all treatment strategies resulting in heart rate reduction improved prognosis, while those accompanied by an increase in heart rate exhibited adverse effects on survival. The significance of heart rate on mortality was retrospectively addressed in sub-analyses of CIBIS II (bisoprolol), MERIT-HF (metoprolol) and the COMET trial (carvedilol/ metoprolol) 20. These large studies enrolled together a total of almost patients with advanced systolic heart failure (NYHA class II IV). The general trend of these three trials clearly demonstrates that high heart rate at rest contributes to poor survival. These experiences are in line with previous studies of â- blockers and other drugs approved in heart failure therapy, demonstrating greater benefits with higher baseline heart rates (>80 bpm) as well as markedly reduced heart rates (>10 bpm) after drug treatment 2. However, it remains currently unknown whether or to what extent the benefit from â-blockers in patients with heart failure is due to heart rate reduction per se or other beneficial effects derived from interrupting maladaptive - â-signaling pathways (apoptosis, fetal gene expression, Ca2 + handling, etc.). A recent metaanalysis aimed at determining whether the survival benefits of â-blockade in heart failure is associated to the magnitude of heart rate reduction or â-blocker dose showed a close relation of outcome with the former, but not the latter 20. As â-blockers considerably reduce heart rate (negative chronotropy) they are most appropriate to be compared with ivabradine, an inhibitor of the I(f) channel acting directly on the sinoatrial node 21. Ivabradine induces a rapid, sustained and dose-dependent reduction of heart rate at rest and during exercise, without significant effects on atrioventricular conduction, left ventricular contraction-relaxation or vascular tissues. Individual experiences with ivabradine can be drawn from case reports dealing with special hemodynamic alterations in heart failure 22. A patient with acute left ventricular decompensation on adequate heart failure medication developed sinus tachycardia (120 bpm) with dyspnoe under dobutamine infusion in the cardiac care unit. Consequently, ivabradine was carefully titrated orally up to a dose of 15 mg/day to reduce heart rate under ongoing dobutamine therapy. Within 5 days heart rate decreased (-34%) with a striking increase in stroke volume (+40%) accompanied by a simultaneously decrease in systemic and pulmonary vascular resistance. After ivabradine withdrawal hemodynamic values worsened again, but readministration of ivabradine led to weaning from dobutamine therapy in the next 3 days and subsequent recovery. Considering these effects it is obvious that a Rev Fed Arg Cardiol 2010; 39 (4):
3 VIEWPOINTS reduction in heart rate could improve the prognosis of heart failure. The BEAUTIFUL study The first prospective mortality and morbidity study on pure heart rate reduction in patients with heart failure and coronary artery disease was published by the BEAUTIFUL (morbidity- mortality EvAlUaTion of the I(f)-inhibitor ivabradine in patients with coronary artery disease and left ventricular dysfunction) investigators 23. This international, multicentric trial was designed as randomized, double-blind, placebocontrolled investigation with patients enrolled who were afflicted with coronary artery disease and left ventricular dysfunction (EF<40%). The aim of the study was to investigate whether lowering heart rate with ivabradine reduces cardiovascular death and morbidity in these patients. The intervention group was treated with 5 mg b.i.d. of ivabradine with a target dose of 7.5 mg b.i.d. The patients continued optimal background medication: ARB-agents (90% of patients), â-blockers (87%), Statins (76%). The mean heart rate at entry was rather low (71.6 bpm), the mean ejection fraction of LV (32.4%) was significantly reduced. The primary endpoint comprised a composite of cardiovascular death, admission to hospital for acute myocardial infarction, admission to hospital for new onset or worsening of heart failure and revascularization. The patients were investigated by intention to treat strategy. Treatment with ivabradine did not reduce the primary composite endpoint compared with standard medical therapy (Fig. 1A). In the subgroup of patients with baseline heart rate higher than 70 bpm (mean 79.2 bpm) ivabradine decreased the risk for fatal and nonfatal acute myocardial infarction (-36%), and the risk of coronary revascularization (-30%) compared with placebo. In contrast to these beneficial results of the subgroup analysis for the vascular endpoint, ivabradine did not improve the morbidity associated with heart failure. A subanalysis of the placebo group of the trial tested the hypothesis that elevated resting heart rate at baseline is a marker for subsequent cardiovascular death and morbidity and confirmed that a resting heart rate >70 bpm is associated with cardiovascular events 8 (Fig. 1B). Patients with elevated heart rates (mean 79.2 bpm) bear higher risks for coronary revascularization (+38%), admission to hospital for myocardial infarction (+46%) or heart failure (+53%), and cardiovascular death (+34%) compared with those with lower heart rates (64.1 bpm). The relatively low baseline heart rate (mean 71.6 bpm) and the small reduction in heart rate (mean 6 bpm) in the BEAUTIFUL study by ivabradine may be an explanation why ivabradine in this study failed to demonstrate improvement in heart failure-related outcomes in patients with stable angina and left ventricular dysfunction. These results may indicate that baseline heart rate possibly due to preexisting â- blockade was too low that I(f)-channel inhibition was unable to gain further therapeutic impact in these patients. The SHIFT study The aim of the SHIFT was to evaluate the effect of additive heart rate reduction by ivabradine in addition to guideline-based treatment on cardiovascular outcomes, symptoms and quality of life in patients with systolic heart failure 24. This international, multicentric trial was designed as randomized, double-blind, placebo-controlled investigation with 6558 patients enrolled who were afflicted with left ventricular dysfunction (EFd»35%, ischemic: 68%, non-ischemic: 32%), sinus rhythm (e»70 bpm) and symptomatic heart failure of more than 4 weeks duration (mainly NYHA Stadium II-III). The intervention group was treated with an average dose of 6.4 mg b.i.d. of ivabradine on top of Figure 1. (A). Composite primary endpoint* in the BEAUTIFULtrial (*cardiovascular death, admission to hospital for acute myocardial infarction and admission to hospital for new-onset or worsening heart failure). (B). Risk for cardiovascular death in the placebo-group of the BEAUTIFUL-trial (adapted from Fox et al. 23 und 8). 260 Rev Fed Arg Cardiol 2010; 39 (4):
4 FLORIAN CUSTODIS ET AL HEART RATE IN THE MANAGEMENT OF HEART FAILURE Figure 2. Composite primary endpoint * in the SHIFT-study 24 (*cardiovascular death or hospital admission for worsening heart failure). optimal standard therapy with ACE-I and ARB agents (about 91% of patients) as well as â-blockers (89%) at the highest tolerated dose. 56% of patients on â-blockers were treated with at least 50% of the guideline based target doses and 26% were at target doses despite explicit recommendation to increase doses by the study committee. Predominant reasons reported for patients not receiving target doses were hypotension and fatigue. Treatment with ivabradine was associated with an average reduction of heart rate of 15 bpm from a baseline value of 80 bpm, which was mainly maintained throughout the course of the trial. Heart rate reduction by ivabradine reduced the risk for the primary composite endpoint of cardiovascular death or hospital admission for worsening of heart failure in the Shift study population by 18% (Fig. 2). This result was mainly driven by hospital admissions for worsening heart failure and occurred within the first 3 months after start of treatment. Moreover heart rate reduction with ivabradine reduced death from heart failure and hospital admissions for worsening heart failure and any other cardiovascular hospital admissions. Cardiovascular mortality was not affected by ivabradine. Corresponding to preceding clinical trials treatment with ivabradine was well tolerated. Fewer serious adverse events occurred in the ivabradine group than in the placebo group. 5% of ivabradine patients had symptomatic bradycardia compared with 1% of the placebo group. Visual side-effects (phosphenes) were reported by 3% of patients on ivabradine and 1% on placebo. A further analysis of the SHIFT data demonstrated that patients with heart rates higher than the mean value (80 bpm) had an increased risk for adverse effects and received greater benefit from ivabradine treatment than those patients with heart rates lower than the median. This finding corresponds to results from â-blocker trials. In patients with systolic heart failure, a continuous relationship between baseline heart rate and adverse outcomes existed. The risk was modified and significantly decreased by heart rate reduction via ivabradine 25 (Fig. 3). At least certain characteristics of the trial leave room for debate. The concomitant â-blocker doses in the study were low. As only 23% of the patients were at target dose and under a half (49%) were receiving 50% or more of the targeted â-blocker dose (despite explicit encouragement by the protocol), the study population rather reflects pattern seen in community practice. Further limitations were a rather low rate of patients Figure 3. Effect of ivabradine compared with placebo on the primary composite endpoint (*cardio-vascular death or hospital admission for worsening heart failure) in the whole patient population, defined by quintiles of baseline heart-rate distribution 25. Rev Fed Arg Cardiol 2010; 39 (4):
5 VIEWPOINTS with devices like implantable cardioverter defibrillators (3%) or cardiac resynchronisation therapy (1%), a low proportion of elderly patients and no patients with atrial fibrillation or flutter. A generalisation of the results to the overall population with chronic heart failure is hardly possible. Consequently the results should be interpreted as the effects of ivabradine in addition to normal clinical practice in the specific population of patients with heart failure and heart rates of 70 bpm or higher, who are unlikely to tolerate the highest dose of â blocker. However the results demonstrated for the first time beneficial effects of additive heart rate reduction on clinical outcomes in patients with chronic heart failure, reduced left ventricular function and a resting heart rate e» 70 bpm. Moreover the study confirms that high heart rate is an independent risk factor in heart failure and an important treatment target. CONCLUSION Clinical and experimental studies support an association between elevated resting heart rate and a broad range of maladaptive cardiovascular effects. Elevated heart rate is one of the key findings in acute and chronic heart failure and has been shown to be an important predictor of morbidity and mortality. Heart rate reduction by â-blockade was shown to reduce mortality and morbidity in heart failure and therefore represents a cornerstone of medical therapy. Despite the high percentage of â-blocker treatment in patients with heart failure therapy, only about one-third of the treated patients are on prescribed â-blocker dose due to side effects and therefore on proper resting heart rate 26. Results of the SHIFT trial showed that heart-rate reduction with the I(f) channel inhibitor ivabradine improves clinical outcomes in patients with chronic heart failure, reduced left ventricular function and a resting heart rate e» 70 bpm. Patients with heart rates higher than the mean value (80 bpm) had an increased risk for adverse effects and received greater benefit from heart rate reduction than patients with heart rates lower than the median. SHIFT proved the concept of heart rate reduction as a therapeutic target in heart failure and provided an alternative for the population of patients with heart failure who are unlikely to tolerate the recommended target dose of â-blockers(25). Several questions remain currently unresolved. It will be important to learn to what extent resting heart rate should be reduced to gain a benefit for patients with heart failure. Further investigations 27 should elucidate whether heart rate reduction alone or together with its specific mode of action (â-blockade, I(f)-channel inhibition, exercise training, etc.). may lead to improved outcome. BIBLIOGRAPHY 1. Heusch G: Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Phamacol 2008; 153: Fox K, Borer JS, Camm AJ, et al: Resting heart rate in cardiovascular disease. JACC 2007; 50: Kannel WB, Kannel C, Paffenbarger RS, et al: Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987; 113: Graham I, Atar D, Borch-Johnsen K, et al: European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: executive summary. Eur Heart J 2007; 28: Reil JD, Custodis F, Swedberg K, et al: Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 2010; Sep. 1 [Epub ahead of print]. 6. Hjalmarson A, Gilpin EA, Kjekshus J, et al: Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: Diaz A, Bourassa MG, Guertin MC, Tardif JC: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: Fox K, Ford I, Steg PG, et al: Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: Custodis F, Baumhäkel M, Schlimmer N, et al: Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atheroslerosis in apoliprotein E-deficient mice. Circulation 2008; 117: Baumhäkel M, Custodis F, Schlimmer N, et al: Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoEknockout mice. Atherosclerosis 2010 [Epub ahead of print]. 11. Beere PA, Glagov S, Zarins CK: Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg- Gaudin F, Tardif JC: Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Phamacol 2008; 154: Böhm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M: Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008; 26: Heusch G, Yoshimoto N: Effects of heart rate and perfusion pressure on segmental coronary resistances and collateral perfusion. Pflugers Arch 1983; 397: Heusch G, Schulz R: The pathophysiological role of heart rate in acute myocardial ischemia and the benefits of heart rate reduction. London-New York, Taylor & Francis Panina G, Khol UN, Nunziata E, et al: Assessment of autonomic tone over a 24-hour period in patients with congestive heart failure: relation between mean heart rate and measures of heart rate variability. Am Heart J 1995; 129: Kaye DM, Lefkovits J, Jennings GL, et al: Adverse consequences of high sympathetic nervous activity in the failing human heart. JACC 1995; 26: Umana E, Solares CA, Alpert MA: Tachycardia-induced cardiomyopathy. Am J Med 2003; 114: Reil JC, Reil GH, Bohm M: Heart rate reduction by I(f)- channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc Med 2009; 19: McAlister FA, Wiebe N, Ezekowitz JA, et al: Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: Rev Fed Arg Cardiol 2010; 39 (4):
6 FLORIAN CUSTODIS ET AL HEART RATE IN THE MANAGEMENT OF HEART FAILURE 21. DiFrancesco D, Camm JA: Heart rate lowering by specific and selective I-f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: Link A, Reil JC, Selejan S, Bohm M: Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol 2009; 98: Fox K, Ford I, Steg PG, et al: Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: Swedberg K, Komajda M, Böhm M, et al: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: Böhm M, Swedberg K, Komajda M, et al: Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebocontrolled trial. Lancet 2010; 376: Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. NEJM 2003; 348: Palatini P, Benetos A, Grassi G, et al: Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: Truth is beautiful; and so are some lies. EMERSON Rev Fed Arg Cardiol 2010; 39 (4):
Trials Enrolled subjects Findings Fox et al. 2014, SIGNIFY 1
Appendix 5 (as supplied by the authors): Published trials on the effect of ivabradine on outcomes including mortality in patients with different cardiovascular diseases Trials Enrolled subjects Findings
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationIs Heart Rate a Treatment Target?
Is Heart Rate a Treatment Target? M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin) Universitätsklinikum des Saarlandes Homburg/Saar michael.boehm@uks.eu Heart Rate
More informationDobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure
Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure Yuksel Cavusoglu, KU Mert, A Nadir, F Mutlu, E Gencer, T Ulus, A Birdane
More informationSemilogarithmic relation between rest heart rate and life expectancy
The importance of heart rate in heart failure Karl Swedberg Professor of Medicine Department t of emergency and cardiovascular medicine i Sahlgrenska Academy University of Gothenburg, Sweden karl.swedberg@gu.se
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationEffects of heart rate reduction with ivabradine on left ventricular remodeling and function:
Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effects of heart rate reduction with ivabradine on left ventricular remodeling and function: results of the SHIFT echocardiography
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More information12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker
12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices Heart Rate as a Cardiovascular Biomarker Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine,
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationManagement of the coronary patient in Roberto Ferrari
Management of the coronary patient in 2011 Roberto Ferrari What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease? Stable angina pectoris
More informationThe Hearth Rate modulators. How to optimise treatment
The Hearth Rate modulators How to optimise treatment Munich, ESC Congress 2012 Prof. Luigi Tavazzi GVM Care&Research E.S. Health Science Foundation Cotignola, IT Disclosure Cooperation with: Servier, Medtronic,
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationSaudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
More informationAdvances in the Monitoring & Treatment of Heart Failure
Advances in the Monitoring & Treatment of Heart Failure Darrell J. Solet, MD - Cardiologist & Medical Director - Cardiovascular Institute of the South of Morgan City, Louisiana - Clinical Assistant Professor
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationNew Drug Evaluation: ivabradine tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe benefit of treatment with -blockers in heart failure is
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial Philippe Lechat, MD, PhD; Jean-Sébastien Hulot, MD; Sylvie Escolano, MD, PhD; Alain Mallet,
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationCase Report Adjuvant Use of Ivabradine in Acute Heart Failure due to Myocarditis
Case Reports in Medicine Volume 2011, Article ID 203690, 4 pages doi:10.1155/2011/203690 Case Report Adjuvant Use of Ivabradine in Acute Heart Failure due to Myocarditis Jennifer Franke, 1 Dorothee Schmahl,
More informationHeart failure. Complex clinical syndrome. Estimated prevalence of ~2.4% (NHANES)
Heart failure Complex clinical syndrome caused by any structural or functional impairment of ventricular filling or ejection of blood Estimated prevalence of ~2.4% (NHANES) Etiology Generally divided into
More informationNew Drug Evaluation: ivabradine tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationCardiogenic shock: Current management
Cardiogenic shock: Current management Janine Pöss Universitätsklinikum des Saarlandes Klinik für Innere Medizin III Kardiologie, Angiologie und internistische Intensivmedizin Homburg/Saar I have nothing
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationEvidence of Baroreflex Activation Therapy s Mechanism of Action
Evidence of Baroreflex Activation Therapy s Mechanism of Action Edoardo Gronda, MD, FESC Heart Failure Research Center IRCCS MultiMedica Cardiovascular Department Sesto S. Giovanni (Milano) Italy Agenda
More informationHeart failure (HF) is a clinical syndrome with enormous relevance given its constantly. Benefits of early treatment with
A low percentage of patients achieve optimal β-blocker doses and optimal heart rate values with β-blocker administration. Ivabradine has been recognized not only for providing a prognostic benefit, but
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationCosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco. Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015
Cosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015 Treatment options for patients with chronic symptomatic
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationManagement of Heart Failure in Adult with Congenital Heart Disease
Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationThe Management of Heart Failure after Biventricular Pacing
The Management of Heart Failure after Biventricular Pacing Juan M. Aranda, Jr., MD University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida Approximately 271,000
More informationBeta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center
Beta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center Beta-blockers: What s known 30 Years 30 Careers Physician clarity regarding
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationChronic. Outline. Congestive^ Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology
Chronic Congestive^ Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationManagement of new-onset AF: Initial rate control treatment
Geneva Acute Crdiovascular Care Congress 2014 - October 18-20, 2014 Management of new-onset AF: Initial rate control treatment Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation,
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR
ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationBUSINESS. Articles? Grades Midterm Review session
BUSINESS Articles? Grades Midterm Review session REVIEW Cardiac cells Myogenic cells Properties of contractile cells CONDUCTION SYSTEM OF THE HEART Conduction pathway SA node (pacemaker) atrial depolarization
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationIncreased heart rate as a risk factor for cardiovascular disease
European Heart Journal Supplements (23) 5 (Supplement G), G3 G9 Increased heart rate as a risk factor for cardiovascular disease Department of Cardiology, VA Medical Center, West Los Angeles, and Department
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationFattori condizionanti la sopravvivenza nel paziente con scompenso di cuore
Journal Club 13 Febbraio 2008 Fattori condizionanti la sopravvivenza nel paziente con scompenso di cuore Intissar Sleiman Prevalence of heart failure by sex and age (NHANES:1999-2004) Circulation 2007
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationAngina Pectoris Dr. Shariq Syed
Angina Pectoris Dr. Syed 1 What is Angina Pectoris (AP)? Commonly known as angina is chest pain often due to ischemia of the heart muscle, Because of obstruction or spasm of the coronary arteries 2 What
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationIvabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice
Adv Ther (2014) 31:961 974 DOI 10.1007/s12325-014-0147-3 ORIGINAL RESEARCH Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical
More informationCardiovascular Disorders. Heart Disorders. Diagnostic Tests for CV Function. Bio 375. Pathophysiology
Cardiovascular Disorders Bio 375 Pathophysiology Heart Disorders Heart disease is ranked as a major cause of death in the U.S. Common heart diseases include: Congenital heart defects Hypertensive heart
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationÀ ². The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 September 2012
À ² The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 September 2012 PROCORALAN 5 mg film-coated tablets B/56 (CIP code: 371 676-2) B/100 (CIP code: 567 208-1) PROCORALAN
More informationHeart rate: an independent risk factor in cardiovascular disease
European Heart Journal Supplements (2007) 9 (Supplement F), F3 F7 doi:10.1093/eurheartj/sum030 Heart rate: an independent risk factor in cardiovascular disease Åke Hjalmarson The Wallenberg Laboratory
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationUpdate on renal denervation: Latest data
LINC 2018 Update on renal denervation: Latest data Felix Mahfoud Saarland University Hospital, Germany Potential Conflicts of Interest I have the following potential conflicts of interest to report: Research
More informationHeart rate lowering treatment in chronic heart failure
Heart rate lowering treatment in chronic heart failure Jaromir Hradec 3rd Dept. Med., Charles Univ., Prague Czech Republic Things we knew, things we did Things we have learnt, things we should do What
More information